Patient-Derived Xenograft - PDX Models

Extensive characterization data in our searchable PDX model database, HuBase™, include: RNAseq of over 1,500 models, whole exome sequencing of over 680 models, histology, growth kinetics, and SoC and investigative treatment data.

PDX Model Largest Sub-Collections

Browse HuBase Database

Evaluate blood cancer therapeutic candidates with validated, stable, truly patient representative leukemia models.

HuKemia is Crown Bioscience’s collection of validated blood cancer PDX models, fully annotated with patient information, diagnosis, and clinical treatments. These models have been fully quality controlled by our pathologists and are available with genotyping and phenotyping data.

Advantages of the HuKemia Blood Cancer PDX Collection

Crown Bioscience’s validated and well-characterized HuKemia models provide many advantages:

• Well-established models that have been used in over 100 preclinical studies, and are therefore a tried and tested approach for assessing preclinical efficacy
• Derived from patients treated with today's clinical therapeutics, including SOC targeted therapies and immunotherapeutics
• Present as stable disease that is transferable through passages, meaning results are highly reproducible across studies
• Overcome limitations with CDX models for systemic diseases. When utilizing CDX models, it can be highly challenging to detect the leukemic cells in the blood, limiting studies to only monitoring survival
• Can be repeatedly challenged to mimic clinical therapy and the emergence of resistance, which means that models of resistance can be created for testing next-generation drugs
• Optional ex vivo assays to leverage access to fresh tumor samples for all AML and ALL models, enabling the assessment of efficient combination and dosing regimens. An illustration of the HuKemia study design followed by ex vivo workflow is shown below

HuKemia Study Design

PDX models for blood cancer are historically very challenging to produce, due to their low take rate in vivo. We overcame these challenges to develop a unique collection of AML and ALL PDX models to better support your preclinical research.

Derived directly from patient bone marrow aspirate, our PDX models better reflect the heterogeneity of leukemia. The models present as stable disease and are transferable through passage. This provides highly reproducible results and availability for repeated studies.

Explore Our Collection

Blood Cancer PDX Characteristics:

Stable models with typical leukemia symptoms and eventual mortality, truly representative of the human condition.Progress targeted agents by choosing PDX models with patient-relevant mutationse.g. IDH2 mutation, FLT3-ITD(+), BCR/ABL(+).Explore extensive model charcterization for pathology, growth characteristics, and response to standard of care and experimental agents.Search for models to meet you research needs through genetic and genomic annotations. Models are charcterized for gene expression, gene copy number, mutations, and fusions.

Stratify Patients for Your Clinical Trials with Population Studies

Over 95% of new drugs fail Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery. Our Translational Oncology Platforms reduce these attrition rates while improving the efficiency of oncology drug development and lowering your developmental costs.

Enhance Your Understanding of How Patients Benefit from Treatment with HuTrials

We provide a preclinical Translational Oncology Technology Platform using the largest HuPrime and HuKemia collection. These are highly characterized and predictive. Ideally used in a Mouse Clinical Trial to identify and understand which patients will benefit from your treatment before you enter the clinic.

Within a HuTrial, each subject reflects the pathology of its original patient, behaving as a patient avatar. The whole cohort of patient avatars represents the diversity of the human patient population.

Log in to explore Crown Bioscience's well-characterized Patient-Derived Xenograft's through our searchable database. Access genomic, molecular, and phenotypic data including tumor growth curves, standard of care response, histopathology data, and patient information on the worlds largest collection

Browse or search our collection to access patient information and model specific characteristics.

×

×

Search PDX genomic information e.g. RNAseq gene expressions data and WES gene copy number data for MET amplification.

×

×

Register Now

Key Benefits:

• Find your interest based on genetic background and response to treatment.
• Test novel therapeutic uses for your existing molecules in over 2,500 models across more than thirty cancer types.
• Start Mouse Clinical Trials immediately, with our PDX model collection consisting of colorectal, esophageal, gastric, head and neck, liver, lung, ovarian, pancreatic cancer, melanoma, sarcoma, and more.
• Discover a PDX model for underrepresented indications, including GIST and prostate cancer.
• Use ALL and AML stable PDX models with typical leukemia symptoms and eventual mortality, truly representative of the human condition.
• Progress your targeted therapy with a unique model of specific disease pathways such as RET, ALK, EGFR, MET, IDH, RSPO, and HER2.
• Start your study without delay across our global operational sites.